Learn more about the exciting field of intratumoral immunotherapy and OncoSec’s role as a key leader in this emerging space.
Watch the Video
OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors
OncoSec Provides 2018 Business Outlook
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
32nd Society for Immunotherapy of Cancer Annual Meeting | November 8-12, 2017
National Harbor, MD
Our core technology platform continues to advance through clinical trials for various cancers.
The ImmunoPulse® platform is designed to boost the immune system to recognize and attack tumors.
OncoSec continues to establish relationships with industry leaders to further advance our research.
PDF | 2.0 MB
PDF | 1.0 MB